Key clinical point: Adding a focal boost to whole-prostate radiation therapy improves outcomes in men with intermediate- or high-risk prostate cancer without increasing late toxicity.

Major finding: The 5-year rate of biochemical disease–free survival was 92% with the addition of the focal boost to the visible tumor versus 85% with standard radiation therapy alone (P < .001).

Study details: A phase 3 randomized controlled trial of 571 men with intermediate- or high-risk prostate cancer (FLAME trial).

Disclosures: The trial was funded by the Dutch Cancer Society and Stand Up Against Cancer Belgium. The principal investigator disclosed no conflicts of interest.